Due to the patent decision Orexo invites to a teleconference
Uppsala, Sweden – September 10, 2018 Due to the patent decision where the US appeal court found Zubsolv´s patent ´330 valid Orexo invites to a teleconference tomorrow September 11 at 3 pm CET. Analysts, investors and media are welcome to attend and listen to president and CEO, Nikolaj Sørensen, commenting the outcome and to hold a Q&A. Questions can also be sent in advance to email@example.com, no later than 2.00 pm CET.
Please view the instructions below on how to participate.
Internet: https://tv.streamfabriken.com/pressconference-orexo. Telephone: (SE) +46 8 5059 6306, (UK) +44 20 313 948 30 or (US) +1 866 928 7517. Pin code: 90656232#
For further information, please contact:
Orexo AB (publ.)
Lena Wange, IR & Communications Manager
Tel: +46 (0)18 780 88 00
Orexo develops improved pharmaceuticals based on innovative drug delivery technologies. The focus is primarily on opioid dependence and pain but the aim is to address therapeutic areas where our competence and technologies can create value. The products are commercialized by Orexo in the US or via selected partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo sells the product Zubsolv®. Total net sales for 2017 amounted to SEK 643.7 million and the number of employees at year-end was 90. Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The head office, where research and development is also performed, is situated in Uppsala, Sweden.
For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.